Acid suppression is the primary therapy for erosive esophagitis (EE). Although proton pump
inhibitors (PPIs) are considered as the first-line medication for EE, 10–20% of patients with …

Background Choosing an optimal reconstruction method is pivotal for patients with gastric
cancer undergoing distal gastrectomy. The uncut Roux‐en‐Y reconstruction, a variant of the …

Background Keverprazan is a novel potassium‐competitive acid blocker (P‐CAB) with a
strong acid‐suppressive capacity that may provide clinical benefit in acid‐related diseases …

Background Proton pump inhibitors (PPIs) have been recommended as standard of care for
reflux esophagitis (RE). Vonoprazan (VPZ), a novel potassium-competitive acid blocker (P …

Rapid development of three-dimensional (3D) printing technique has enabled the
production of many new materials for medical applications but the dry laboratory surgical …

Gastroesophageal reflux disease (GERD) is a widely prevalent gastrointestinal disorder,
affecting∼ 13.3% of the global population. There are shortages and limitations of current …

Objectives Anti‐reflux mucosectomy (ARMS) is an emerging and promising endoscopic
treatment for gastroesophageal reflux disease (GERD). In the current study we aimed to …

Antecedentes La enfermedad por reflujo gastroesofágico (ERGE) es muy prevalente en la
población general, se presenta con un amplio espectro de manifestaciones clínicas que …

Gastroesophageal reflux disease (GERD) is common worldwide and poses a huge
challenge to health. Consensuses and guidelines on the diagnosis and management of …

Background: Proton-pump inhibitors (PPIs) and potassium-competitive acid blockers (P-
CABs) are recommended for erosive esophagitis (EE), with good safety and tolerance …